Peptide Based Gastrointestinal Disorders Therapeutics Market Offering Trends, Share, Size and Growth until the End of 2022

Posted on 2018-07-03 by Mark Hub in Healthcare, Industrial // 0 Comments

Fact.MR

Dublin 2, Ireland, 2018-Jul-03 — /EPR Network/ — FactMR research firm has recently updated its massive report catalogue by adding a fresh study titled “Peptide Based Gastrointestinal Disorders Therapeutics Market Forecast, Trend Analysis & Competition Tracking: Global Review 2017 to 2022”. This business intelligence study encapsulates vital details about the market current as well as future status during the forecast period of 2017-22. Readers can expect holistic and comprehensive analysis on the peptide based gastrointestinal disorders therapeutics market, which can be used for formulating effective business strategies. The report also targets important facets such as market drivers, challenges, latest trends, and opportunities associated to growth of manufacturers in global market for peptide based gastrointestinal disorders therapeutics.

Highlights of the Report Include:

North America currently commands for the largest share of the global market in terms of revenue and the trend is likely to continue over the next five years. The region’s market is expected to expand at little under 14% CAGR over the forecast period. This growth is attributed to the rising adoption of peptide based drugs and increasing patient awareness about new and novel therapeutic treatments.

Request Free Sample Report- https://www.factmr.com/connectus/sample?flag=S&rep_id=190

Based on drugs, global sales of linaclotide for treatment of gastrointestinal ailments is significantly high. Sales of linaclotide currently commands for over two-third revenue share of the global market. By the end of 2022, over US$ 466 Mn worth linaclotide peptide drugs are estimated to be sold across the globe.

Hospital pharmacies is expected to remain the most attractive distribution channel for peptide based gastrointestinal disorders therapeutic drugs throughout the assessment period. In terms of revenue, hospital pharmacies currently account for nearly 50% share of the global market and the figure is unlikely observer any major alteration over 2022. Meanwhile, retail pharmacies will continue to hold the second position and reflect an impressive growth during the five years of forecast.

Browse Full Report with TOC- https://www.factmr.com/report/190/peptide-based-gastrointestinal-disorders-therapeutics-market

North America to Lead the Global Peptide Based Gastrointestinal Disorders Therapeutics Market

In terms of revenue, North America is expected to hold the dominant share of the global peptide based gastrointestinal disorders therapeutics market in 2017 and beyond. Factors such growing patient awareness and rapid adoption of peptide based therapeutics for treating various diseases are expected to support the growth of the market in the region. During the forecast period, the market in the region is projected to surge at a robust CAGR of 13.9%.

On the basis of drugs, the linaclotide segment is expected to retain its dominant position over 2022. Currently, the segment accounts for more than two-third share of the market in terms of revenue. Towards the end of the forecast period, the linaclotide segment is estimated to reach a market valuation in excess of US$ 466 Mn.

Competition Tracking

Shire plc, Ironwood Pharmaceuticals, Inc., Astellas Pharma Inc., Allergan plc, Accredo Health Group, Inc., are the key market players profiled in the Fact.MR’s report. A majority of these companies are channelizing investment in further expansion of their product portfolio. This, in turn, is anticipated to result in introduction of more efficacious peptide based therapeutic drugs for curing gastrointestinal ailments.

Buy this Report- https://www.factmr.com/checkout/190/S

About FactMR

FactMR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized Healthcare market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that’s why we publish multi-industry global, regional, and country-specific research reports.

Matched content

Editor’s pick